GSK first quarter
This article was originally published in The Tan Sheet
Executive Summary
Pharma company's smoking cessation unit recovered from a disappointing fourth quarter 2003 and advanced 17% in the first quarter 2004 to drive Consumer Healthcare revenues up 6% to $1.3 bil. Boosted by NRT products, OTC medicine sales were ahead 2% to $627.3 mil. Analgesic sales rose 12%, helping to offset an 18% drop in dermatological product sales. Oral care sales increased 6% to $462 mil. based on strong performances of Aquafresh and Sensodyne. Nutritional healthcare grew 13% due to strong international and European growth. ...